Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.57 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.53 |
| ▸ | RRM1 | P23921 | 1/20 | 0.51 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450582 | 0.98 | GNAI3 (0.59) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL4759296 | 0.86 | DPP7 (0.44) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL15189444 | 0.85 | GNAI3 (0.57) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL9905435 | 0.84 | DPP7 (0.44) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL3229876 | 0.84 | RRM1 (0.46) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL15195578 | 0.84 | PRMT1 (0.55) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL16124667 | 0.84 | DPP7 (0.69) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL23077487 | 0.83 | DPP7 (0.44) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL1374079 | 0.83 | DPP7 (0.44) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL1976979 | 0.82 | DPP7 (0.67) | GNAI3GNAO1GNAI1DPP7RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4378536-A2 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-3169403-B1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11884748-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20210363185-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10941183-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10787490-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | Protaganist Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200064357-A1 | METHODS FOR DETERMINING AND MONITORING GASTROINTESTINAL INFLAMMATION | PROTAGONIST THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190337983-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2019-11-07 | — | — | US | disclosed |
| EP-3341011-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2018089693-A2 | METHODS FOR DETERMINING AND MONITORING GASTROINTESTINAL INFLAMMATION | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180079783-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180079782-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| EP-3169403-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9624268-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017011820-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2016011208-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884748-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | GNAI3 705/4885GNAO1 3273/4885GNAI1 1485/4885 |
| US-20190337983-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | GNAI3 705/4885GNAO1 3273/4885GNAI1 1485/4885 |
| US-20180079783-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | GNAI3 515/4885GNAO1 3212/4885GNAI1 1134/4885 |
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | GNAI3 705/4885GNAO1 3273/4885GNAI1 1485/4885 |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | GNAI3 515/4885GNAO1 3212/4885GNAI1 1134/4885 |
| US-20210363185-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | GNAI3 705/4885GNAO1 3273/4885GNAI1 1485/4885 |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | GNAI3 515/4885GNAO1 3212/4885GNAI1 1134/4885 |
| US-10787490-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, IL36G | GNAI3 761/4885GNAO1 3582/4885GNAI1 1355/4885 |
| US-10941183-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | GNAI3 705/4885GNAO1 3273/4885GNAI1 1485/4885 |
| US-20180079782-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | GNAI3 515/4885GNAO1 3212/4885GNAI1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.